NCT00761319View on ClinicalTrials.gov

Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health

PHASE3CompletedINTERVENTIONAL
Enrollment

705

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Open-angle GlaucomaOcular Hypertension
Interventions
DRUG

Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.

DRUG

Latanoprost ophthalmic solution 0.005% (XALATAN®)

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY